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Paternal RHD zygosity determination in Tunisians: 
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Narjes Kacem1,2,3, Saloua Jemni-Yacoub3, Jacques Chiaroni1,2, Pascal Bailly1,2, Monique Silvy1,2
1French Blood Institute-Alpes-Méditerranée, Marseille; 2UMR 7268 ADES, Aix-Marseille Université-EFS-CNRS, 
Marseille, France; 3Regional Blood Transfusion Centre, Research Unit "UR06SP05", Sousse, Tunisia
Background. The choice of a molecular test for first intention determination of paternal RHD 
zygosity, before entering into invasive diagnostics, is important for the management of pregnancies 
at risk of haemolytic disease of the foetus and newborn related to anti-RhD.
Materials and methods. RHD zygosity was evaluated in 370 RH:1 Tunisian donors by polymerase 
chain reaction - sequence-specific polymorphism (PCR-SSP) analysis and polymerase chain reaction 
- restriction fragment length polymorphism (PCR-RFLP) amplification of hybrid Rhesus box and by 
real time quantitative polymerase chain reaction (RQ-PCR) specific for RHD exon 5. To evaluate 
the accuracy of molecular tests in the cases of discordant results, the ten exons of RHD and Rhesus 
boxes were amplified by PCR and sequenced.
Results. Molecular investigations revealed that our 370 donors comprise 193 dizygous and 145 
hemizygous individuals and 32 subjects whose zygosity remains unknown. Positive predictive values 
were higher than 99% for all the methods, reaching 100% for RQ-PCR. Negative predictive values 
were 83.24%, 87.27% and 98% for PCR-SSP, PCR-RFLP and RQ-PCR respectively. This study 
also revealed 19 novel Rhesus box polymorphisms and three novel RHD alleles: RHD(Trp185Stop), 
RHD(Ala176Thr) and RHD(Ile342Ile). 
Discussion. RQ-PCR is the most convenient method for first intention determination of paternal 
RHD zygosity in Tunisians. However, taking into account positive and negative predictive values, PCR-
RFLP could be an alternative despite the heterogeneity of Rhesus boxes  and the complexity of RHD.
Keywords: zygosity, RHD alleles, Rhesus box polymorphisms.
Introduction
RhD is a complex blood group antigen and anti-D has 
been implicated in haemolytic disease of the foetus and 
newborn (HDFN). Adoption of antenatal and postpartum 
use of Rh immune globulin in industrialised countries 
has resulted in a major decrease in the frequency of this 
disease1. In Tunisia, HDFN due to RhD immunisation 
is currently prevented in the vast majority of cases by 
administration of anti-D immunoglobulin to D-negative 
women within 72 hours of delivery of a RhD-positive 
neonate as well as in cases of abortion2. Systematic 
antenatal prophylaxis could enhance the prevention 
for all pregnant women but this strategy could create a 
shortage in anti-D immunoglobulin and carry significant 
potential costs. In order to develop an antenatal 
prophylaxis limited to foetuses that are potentially at 
risk of HDFN related to anti-D, it has been proposed 
that paternal zygosity could be determined as the first 
step in the management of the red cell alloimmunised 
pregnancy3. If the father is found to have a heterozygous 
genotype, genetic testing could be undertaken, through 
amniocentesis, to determine whether the foetus is at 
risk of foetal anaemia. The overall sensitivity and 
specificity of polymerase chain reaction (PCR) typing on 
amniotic fluid has been reported to be 99.5% and 98.6%, 
respectively, and both positive and negative predictive 
values were 99.1%4. However this invasive procedure 
is risky and might cause further sensitisation in RhD-
negative women. RHD zygosity was once determined 
through serological testing using population statistics. 
Ethnicity played a major role in these calculations and 
recently molecular tests, which circumvent this issue, 
were shown to be more accurate5,6. A general problem 
concerning determination of the zygosity of the father 
is non-paternity. However, in a conservative society 
such as Tunisia, non-paternity is unlikely. The newest 
technology used in the determination of the foetal RhD 
type in the case of heterozygous paternity involves free 
foetal DNA in the maternal circulation. Based on the 
concept that cell-free tumour DNA could be found in 
the peripheral circulation of patients with cancer, Lo 
et al.7 were the first to report the presence of the RHD 
gene in the plasma of women pregnant with a RhD-
positive foetus. Detection of foetal RHD in maternal 
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plasma is used as a non-invasive method for assessing 
the risk of HDFN, but a remaining pitfall that hampers 
its use is the limited reliability of negative results since, 
without an internal control, true negative results cannot 
be distinguished from false negative results due to 
insufficient amounts of free foetal DNA. A recent report 
described the use of single nucleotide polymorphisms as 
internal controls, but a large study using this strategy is 
lacking8. Moreover, non-invasive antenatal diagnostic 
testing to target anti-D prophylaxis was shown to be 
unlikely to produce important clinical benefits and its 
reliability in different ethnic minority populations needs 
to be demonstrated rigorously9. 
Since RHD is a very polymorphic gene attention 
should be paid to the specificity and sensitivity of 
molecular tests. In Caucasians, the most common 
mechanism of RH:-1 phenotype is deletion of the RHD 
gene10 occurring as a result of unequal crossing-over 
between the two Rhesus boxes flanking the RHD gene. 
This leaves a single hybrid Rhesus box as a target for 
RHD zygosity testing and detection of this hybrid Rhesus 
box has been used to demonstrate the presence of the 
RHD deletion, making it possible to distinguish RHD 
dizygous individuals from RHD hemizygous ones11. 
Different approaches to detect the hybrid Rhesus box 
have been described, but these molecular methods may 
lead to false results in Africans because of their large 
genetic diversity12.
RHD deletion was shown to be the main background 
of the RH:-1 phenotype in the Tunisian population13 
suggesting that paternal RHD zygosity in Tunisians 
could be determined using molecular methods that are 
accurate in Caucasians. To identify the most accurate 
and reliable method for RHD zygosity assignment 
in Tunisians, RHD zygosity was determined in 405 
Tunisian donors. Three molecular methods, based 
on polymerase chain reaction - sequence-specific 
polymorphism (PCR-SSP) analysis, polymerase chain 
reaction - restriction fragment length polymorphism 
(PCR-RFLP) amplification and real-time, quantitative 
polymerase chain reaction (RQ-PCR) specific for the 
RHD exon 5, were compared.
Materials and methods
Blood sampling, serological typing and DNA 
extraction
A total of 405 random EDTA blood samples were 
collected from blood donors recruited with informed 
consent according to the approved protocol of the 
Regional Blood Transfusion Centre of Sousse (Tunisia) 
to determine RHD zygosity. RhD phenotyping was 
routinely done as described in our previous study6 
and the indirect antiglobulin test was performed 
systematically for apparently RH:-1 results. Genomic 
DNA was isolated from buffy coats by a salting-out 
method according to a standard protocol14.
Polymerase chain reaction - sequence-specific 
polymorphism analysis for the hybrid Rhesus box
A 2778 bp product was amplified using forward primer 
u1-s15, which is specific for the hybrid and upstream 
Rhesus boxes, and reverse primer rnb31, which is specific 
for the hybrid and downstream Rhesus boxes (Figure 1). 
The PCR was performed as previously described6.
Polymerase chain reaction - restriction fragment 
length polymorphism analysis for hybrid and 
downstream Rhesus boxes 
The PCR-RFLP method was performed as described 
by Wagner and Flegel11. A 3,029 bp product was 
amplified using primers rez7 (universal primer for 
all Rhesus boxes) and rnb31 for amplification of the 
Figure 1 - Localisation of primers in the hybrid Rhesus box. Nucleotide 5250 represents the location of the PstI 
site used in the PCR-RFLP. Nucleotide positions are given corresponding to the standard downstream 
Rhesus box where position 1 represents the start of the homology between upstream and downstream 
Rhesus boxes and corresponds to nucleotide number 23 in GenBank accession number AJ252312.
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downstream and/or hybrid Rhesus boxes (Figure 1). 
The PCR amplicon was digested with 1.5 U/µL of Pst 
I (Fermentas, St. Leon-Rot, Germany) overnight at 
37 °C and fragments were resolved using a 2% (w/v) 
agarose gel.
Real-time quantitative polymerase chain reaction 
analysis for RHD exon 5
Primers and probes for RHD exon 5 and CCR5 
genes were from Finning16. The probes for RHD exon 
5 and CCR5 were labelled with 6-FAM and Yakima 
yellow, respectively. Each primers was used at a final 
concentration of 300 nM and probes specific for RHD 
exon 5 and CCR5 were used at a final concentration of 
200 nM and 100 nM, respectively. After 10 minutes at 
95 °C, the reaction consisted of 40 cycles (95 °C for 10 
sec and 60 °C for 30 sec). The MagNA Pure LC system 
(Roche Diagnostics, Indianapolis, IN, USA) was used 
to dispense master mix (TaqMan®, Applied Biosystems, 
Courtabœuf, France) and DNA (100 ng) in triplicate. 
Relative quantification (∆Cq) was done with CCR5 
as the control gene and compared to results of control 
samples with one or two copies of the RHD gene17.
Genomic analysis of the RHD gene
To determine zygosity in discordant samples the ten 
exons of RHD were amplified by PCR and sequenced. 
Each exon amplification was performed using the primer 
sets described by Touinssi et al.18.
Sequencing analyses of the Rhesus boxes
With the aim of explaining discordant results, 
Rhesus boxes were amplified by PCR and sequenced 
using two PCR sets (Figure 1): PCR1 was applied with 
primers CRBF06 and CRBR0812 and PCR products 
were sequenced with the same couple of primers; PCR2 
was done with Rez7 and CRBR02 primers12 and PCR 
products were sequenced with Rez7 and CRBF04-R 
(5'cctctgccagggcagtgca3') primers. 
Statistical analysis
The positive predictive value (PPV) was calculated 
for samples with no hybrid Rhesus Box detected by PCR-
SSP and PCR-RFLP and for samples with two expressed 
alleles by RQ-PCR using the following formula:
PPV=(Number of samples with two non-silent RHD 
alleles)/(Number of samples with two non-silent RHD 
alleles+Number of samples with one non-silent RHD 
alleles).
The negative predictive value (NPV) was calculated 
for samples with one hybrid Rhesus Box detected by 
PCR-SSP and PCR-RFLP and for samples with one 
expressed alleles by RQ-PCR based on the same formula 
as that for the calculation of the PPV.
Results
RhD phenotype
RhD phenotyping of 405 donors randomly recruited 
from the centre of Tunisia revealed that 370 had the 
RH:1 phenotype and 35 had the RH:-1 phenotype. All 
RH:-1 phenotypes were confirmed through indirect 
antiglobulin testing.
Analysis of the RH:-1 samples
The RH:-1 samples (n=35) were used as controls for 
the PCR-SSP, PCR-RFLP and RQ-PCR analyses. PCR-
SSP detected the hybrid Rhesus box in all RH:-1 samples. 
PCR-RFLP showed homozygous RHD gene deletion in 
32 RH:-1 samples and three samples containing a single 
copy of hybrid Rhesus box. Sequencing of these samples 
showed a DIIIa-CE(4-7)-D, a weak D type 4.0 (omitted 
by serological techniques), and a new allele with a 
nucleotide change in RHD exon 7 at position 1026C/T 
(RHD [Ile342Ile]). According to the RQ-PCR analysis, 
RHD exon 5 was absent in 33 samples and present in 
weak D type 4.0 and RHD (Ile342Ile). 
Analysis of the RH:1 samples
The comparison between the three methods for 
RHD zygosity assignment showed concordant results in 
303 samples (81.9%). Discordant results (n=67, 18.1%) 
were classified into three groups (Figure 2). Group 1 
(n=31) consisted of samples with results obtained by 
PCR-SSP similar to those obtained by PCR-RFLP but 
different from those obtained with RQ-PCR. Twenty-
six samples had one copy of RHD gene by both PCR-
SSP and PCR-RFLP and two copies by RQ-PCR, and 
five had two copies of RHD gene by both PCR-SSP 
and PCR-RFLP and one copy by RQ-PCR. Group 2 
contained 12 samples with discordant PCR-SSP and 
RQ-PCR findings and without results in PCR-RFLP. 
We distinguished four samples in which the zygosity 
status differed in one copy of RHD gene by PCR-
SSP and eight samples showing two copies. Group 
3 consisted of 24 samples whose results obtained by 
PCR-RFLP were similar to those obtained by RQ-PCR 
but differed from those obtained by PCR-SSP.
RHD sequencing results
RHD sequencing of the ten exons in 67 discordant 
samples are shown in Figure 2. All the RHD 
variants observed were heterozygous in trans to 
conventional RHD. We identified three new variants: 
(i) RHD(Trp185Stop): a G>A transition at position 555 
leading to a stop codon; (ii) RHD(Ile342Ile): a 1026C>T 
transition in RHD exon 7, and (iii) RHD(Ala176Thr): a 
G>A transition at position 526 in RHD exon 4.
We also identified a probable weak D type 4.0 
(nucleotide changes: 667T>G in RHD exon 5, 819G>A 
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in RHD exon 6 because RHD exon 2 and 4 amplifications 
failed). We found homo/hemizygous intronic single 
nucleotide polymorphisms (n=10) and heterozygous 
intronic single nucleotide polymorphisms (n=18). We 
were unable to identify seven samples, probably because 
of the quality of the DNA. 
In conclusion, zygosity remained unknown for 37 
subjects: homo/hemizygous intronic single nucleotide 
polymorphisms (n=10), no single nucleotide polymorphisms 
(n=20), and genotyping failure (n=7). Therefore, 189 
subjects were dizygous and 144 were hemizygous.
 
Rhesus boxes polymorphisms for RH:1 discordant 
samples
Since RHD genotyping failed in seven samples, only 
the remaining 60 discordant samples were analysed 
for Rhesus box polymorphisms by PCR1 and/or PCR2 
(Figure 2). No single nucleotide polymorphism was 
observed at the 5' part of Rhesus boxes in three samples 
(5%, with RHD/RHD(Ala176Thr), heterozygous 
intronic single nucleotide polymorphism in IVS1 and 
in IVS1+IVS8), whereas Rhesus boxes were mutated 
in 57 samples (95%). Table I summarises the different 
nucleotide positions of mutated Rhesus boxes in RH:1 
discordant samples. In addition to single nucleotide 
Figure 2 - Classification and analysis of discordant results.
polymorphisms reported by Wagner et al.19, we 
identified 19 new polymorphisms in Rhesus boxes, listed 
and underlined in Table I. 
Observation of polymorphisms under rnb31 led us to 
assign a hemizygous status to one subject and a dizygous 
status to four subjects whose zygosity was previously 
unknown. Thus, zygosity remained unknown for 32 
subjects because of homo/hemizygous intronic single 
nucleotide polymorphisms (n=7), genotyping failure 
(n=7) and no single nucleotide polymorphism in the 
RHD gene (n=18). Of the remaining 338 samples, 193 
were dizygous and 145 hemizygous.
Positive and negative predictive values of the three 
methods
The PPV and NPV were calculated for each 
technique using the 338 samples with known zygosity 
(Table II). The PPV were higher than 99% for all 
methods, reaching 100% for RQ-PCR. The NPV were 
83.24%, 87.27% and 98% for PCR-SSP, PCR-RFLP and 
RQ-PCR, respectively.
Discussion
Antibodies to the RhD antigen can be produced 
during pregnancy in a RhD-negative mother carrying 
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a RhD-positive foetus, in particular following 
foetal-maternal haemorrhage at birth. While the first 
baby is usually not harmed, these antibodies may 
cause HDFN in subsequent RhD-positive babies. RhD 
incompatibility is a major cause of HDFN. Establishing 
paternal RHD zygosity to determine the risk of HDFN 
related to anti-D has the advantage of predicting the risk 
of HDFN in future pregnancies. Indeed, if the father is 
homozygous for the RHD gene (dizygous), the chance 
of inheriting the RHD gene is 100% for each pregnancy. 
Conversely, in the case of a hemizygous father (RHD/d) 
the risk is 50%. The aim of the present study was to assess 
the most convenient molecular method for determination 
of RHD zygosity in the Tunisian population as a method 
of first intention for the evaluation of HDFN risk. 
 Analysis of 370 random RhD-positive Tunisians 
using three molecular tests showed 81.9% concordant 
results and through investigation of RHD alleles 
and Rhesus box polymorphisms in the 67 discordant 
samples we concluded that our cohort consisted of 193 
dizygous subjects, 145 hemizygous individuals and 32 
subjects whose zygosity remains unknown because of 
lack of heterozygous single nucleotide polymorphisms 
or technical failure. Based on the 338 samples with 
known zygosity, the PPV, NPV and Youden index were 
calculated for each molecular test. The highest Youden 
index was observed for RQ-PCR (0.98) showing that 
this method was the most reliable and convenient for the 
Tunisian population. However, taking into account the 
high PPV (99.4%) and despite the lower NPV (87.27%) 
of PCR-RFLP, this method could be an alternative to 
the use of RQ-PCR for determining RHD zygosity 
in Tunisia. If the father is found to be hemizygous, 
second intention invasive methods would then be used 
to evaluate the risk of HDFN. Thus, in cases of falsely 
labelled hemizygous fathers, invasive investigations 
will be performed uselessly correcting the false zygosity 
assignment of the first intention test. Since some RHD 
variant alleles in the Tunisian population were shown 
to be related to some in Caucasians, we suggest that the 
false negative results using RQ-PCR (n=3) could be 
linked to presence in trans to a conventional RHD allele 
of a hybrid RHD-CE-D gene, such as DVI type 1 or 2 
which are the most frequent partial alleles encountered 
in Caucasians20,21. In the heterozygous state such a hybrid 
gene cannot be distinguish by either haemagglutination 
tests or DNA analysis. False positive and false negative 
results using PCR-SSP and PCR-RFLP were the result 
of: (i) mutations in Rhesus boxes leading to lack of 
amplification of hybrid Rhesus boxes, and (ii) the 
presence of non-functional RHD alleles from African 
origin leading to an incorrect estimation of the risk of 
HDFN.
The present study also led to the identification 
of three novel RHD alleles: RHD(Trp185Stop), 
RHD(Ala176Thr) and RHD(Ile342Ile). Because of the 
premature stop, RHD(Trp185Stop) is predicted to be a 
silent allele which is associated with over-estimation 
of HDFN risk in the context of zygosity determination. 
RHD(Ala176Thr) is predicted to encode a weak 
phenotype since amino-acid 176 is located in the fifth 
transmembrane helix22. However, since these alleles 
were in trans to conventional RHD, no serological 
investigations were performed and we have no certainty 
about the RhD phenotype associated with these alleles. 
Allele encoding RHD(Ile342Ile) was found in two 
samples. Despite the silent nature of the polymorphism 
one of the donors bearing this allele typed as RhD-
negative. Unfortunately, no blood sample was available 
for verification of serological results and no conclusion 
can be made based only on the molecular analysis. This 
study also demonstrated the complexity of Rhesus boxes 
Table II - Positive and negative predictive values and Youden index for the three molecular methods.
Two non-silent
RHD alleles
One non-silent
RHD allele PPV NPV Youden index
HDFN risk High (100%) Moderate (50%)
Need for amniocentesis No Yes
PCR-SSP
No hybrid Rhesus box detected 164 1
99.39 83.24 0.84
One hybrid Rhesus box detected 29 144
PCR-RFLP
No hybrid Rhesus box detected 167 1
99.4 87.27 0.88
One hybrid Rhesus box detected 21 144
RQ-PCR
Two expressed alleles 188 0
100 98 0.98
One expressed alleles 3 147
Positive predictive value (PPV), negative predictive value (NPV) and Youden index were calculated using: http://www.aly-abbara.com/utilitaires/statistiques/
sensibilite_specificite_vpp_vpn.html.
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with the description of 19 novel polymorphisms. The 
heterogeneity of Rhesus boxes highlights the limitations 
of Rhesus box approaches to the determination of RHD 
zygosity.
Altogether, the results of our analysis of 338 random 
samples with known zygosity demonstrated that 
RQ-PCR can accurately assign zygosity status of samples 
in Tunisians. In the case of determination of paternal 
zygosity, RQ-PCR enables prediction of the risk that a 
foetus will inherit RHD and will be useful in identifying 
HDFN cases which may require further genotyping. 
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